Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 injection plus chemotherapy ± anlotinib as first-line treatment for advanced endometrial cancer
CTR20221688Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in endometrial cancer (EC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2022; status: completed.
02
Drugs
benmelstobart
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20221688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221688.